Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma

• Published in: Critical reviews in oncology/hematology Vol. 92; no. 3; pp. 208 - 217
• Main Authors: Guida, Fancesco Maria, Santoni, Matteo, Conti, Alessandro, Burattini, Luciano, Savini, Agnese, Zeppola, Tea, Caricato, Marco, Cascinu, Stefano, Tonini, Giuseppe, Santini, Daniele
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ireland Ltd 01.12.2014
• Subjects: Alternative schedule; Angiogenesis Inhibitors - administration & dosage; Antineoplastic Agents - administration & dosage; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Drug Administration Schedule; Hematology, Oncology and Palliative Medicine; Humans; Indoles - administration & dosage; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Metastatic renal cell carcinoma; Neoplasm Metastasis; Pyrroles - administration & dosage; Sunitinib; Treatment Outcome; Two weeks on/one week off; Metastatic renal cell carcinoma; Sunitinib; Two weeks on/one week off; Alternative schedule
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2014.07.006

Highlights • This review discusses the efficacy of alternative regimens to the standard 4/2 schedule of Sunitinib. • This review discusses the tolerability of alternative regimens to the standard 4/2 schedule of Sunitinib. • The 2/1 schedule may become the future sunitinib standard regimen for mRCC patients. • The ideal schedule for single patient seems still so far due to the lack of biological insights.